title: Simultaneous integrated boost intensity-modulated radiotherapy for treatment of locally advanced non-small-cell lung cancer: a retrospective clinical study.
abstract: OBJECTIVE
  To evaluate the clinical efficacy and safety of simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) for patients with locally advanced non-small-cell lung cancer (LANSCLC).
  
  
  METHODS
  48 patients with LANSCLC treated with SIB-IMRT from January 2010 to April 2012 were retrospectively analysed. A radiation dose of 45-63 Gy (median dose, 51.58 Gy) was delivered to the planning target volume (1.8-2.0 Gy daily fractions) simultaneously with 55.0-74.2 Gy (median dose, 63 Gy) to the planning gross tumour volume (2.00-2.25 Gy daily fractions). 45 patients received concurrent/sequential chemotherapy. The overall survival (OS), locoregional recurrence-free survival (LRFS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Treatment-related pneumonitis and oesophagitis were graded according to the Common Terminology Criteria for Adverse Events v. 4.0.
  
  
  RESULTS
  By 1 July 2013, 29 of the 48 patients were dead. The median follow-up time for the survivors was 28 months (19-44 months). The median OS and PFS were 21 and 14 months, respectively. The median LRFS time was not reached. The 2-year LRFS, OS and PFS were 62.5%, 45.1% and 28.0%, respectively. Two patients experienced Grade 3 treatment-related pneumonitis, two patients experienced Grade 5 treatment-related pneumonitis and two patients had ≥Grade 3 oesophagitis.
  
  
  CONCLUSIONS
  SIB-IMRT appears to be an effective therapeutic option in patients with LANSCLC and warrants further evaluation with increased number of patients in prospective clinical trials.
  
  
  CONCLUSIONS
  This study explores the feasibility of delivering tumoricidal doses of radiation to primary lesions in non-small-cell lung cancer.
authors.affiliation: Department of Pain Relief, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, and Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
authors.forename: K
authors.initials: K
authors.lastname: Ji
authors.forename: L J
authors.initials: LJ
authors.lastname: Zhao
authors.forename: W S
authors.initials: WS
authors.lastname: Liu
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Liu
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Yuan
authors.forename: Q S
authors.initials: QS
authors.lastname: Pang
authors.forename: J
authors.initials: J
authors.lastname: Wang
authors.forename: P
authors.initials: P
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D004941:Esophagitis / Q000209:etiology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D017564:Radiation Pneumonitis / Q000209:etiology; D011879:Radiotherapy Dosage; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects; D012189:Retrospective Studies; D016019:Survival Analysis